12.20.19
Evotec SE has successfully achieved a third milestone in its diabetes research alliance with Sanofi (TargetBCD), resulting in a €3 million payment to Evotec.
Evotec met pre-agreed critical criteria within the beta cell replacement therapy program. The goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms."
The companies entered the research alliance in August 2015 to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells for diabetes. Both companies have made significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration extends Evotec's metabolic disease and stem cell-based drug discovery programs. To date, Evotec has received €12 million in upfront and milestone payments from Sanofi, as well as substantial research funding.
Evotec met pre-agreed critical criteria within the beta cell replacement therapy program. The goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms."
The companies entered the research alliance in August 2015 to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells for diabetes. Both companies have made significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration extends Evotec's metabolic disease and stem cell-based drug discovery programs. To date, Evotec has received €12 million in upfront and milestone payments from Sanofi, as well as substantial research funding.